Scintomics Molecular, Applied Theranostics Technologies (SCI-att)
Scintomics Molecular, Applied Theranostics Technologies (SCI-att) is a growing player in the radiopharmaceutical business with a particular strategic emphasis on providing unrestricted supply and support of proprietary and innovative tracer technology and non-IP protected precursors, such as PSMA I&T and next generation PSMA inhibitors for radioligand therapy such as siPSMA-14.
The well-known GRP Module Series became part of SCI-att in 2020 when SCI-att took over the Module business from its parent company Scintomics, which has been selling and installing fully automated production systems for established radio-pharmaceuticals in clinical facilities around the world since 2006.
To continue our strong track record of successful Synthesis Modules and expand our portfolio of tracers we are excited to launch our smartGRP. The smartGRP is a cost-effective alternative for doing standard syntheses, such as [68Ga]- and [177Lu]-labelling-peptides. In addition, it can also be used for the syntheses that the siGRP offers.
The new model is designed with the intent of offering the usual GRP feeling while also allowing for several upgrade options.
We look forward to welcoming you at our booth!